Testing combined treatment for lung cancer that returned after initial therapy

Plain-English translation of NCT07279935 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated June 2026 · How we translate trials

Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.

What is this trial?

This study is for patients with a specific type of lung cancer (nonsquamous non-small cell lung cancer with EGFR mutations) whose cancer came back in distant parts of the body after finishing initial treatment with osimertinib. The trial tests whether osimertinib combined with chemotherapy can help control the cancer that has returned. Researchers will look at your cancer's specific genetic profile to guide the best treatment approach.

Some patients whose lung cancer initially responds well to osimertinib eventually experience their cancer returning in distant areas of the body. This study aims to find out whether combining this medication with chemotherapy can be more effective at treating cancer that has recurred after the initial osimertinib treatment.

Do you qualify?

You likely qualify if…

you had lung cancer surgery followed by osimertinib treatment that you completed or stopped before finishing the full 3-year course
your cancer has come back in distant parts of your body at least 6 months after stopping osimertinib
testing confirms your cancer has EGFR mutations (specifically Exon 19 deletion or L858R mutation)
you have not received any other chemotherapy or cancer drugs since finishing your initial osimertinib treatment
you are at least 18 years old with a life expectancy of more than 12 weeks
you have a nonsquamous type of non-small cell lung cancer

You likely don't qualify if…

your cancer has only come back in the same area or nearby lymph nodes (not distant)
you have symptomatic brain metastases or spinal cord compression causing symptoms
you have a history of severe lung inflammation or lung disease that required steroid treatment
you cannot swallow pills, have severe nausea and vomiting, or have bowel problems that would prevent you from absorbing the medication properly
you stopped your previous osimertinib treatment because of serious side effects

What participation looks like

You would take osimertinib combined with chemotherapy (pemetrexed and either cisplatin or carboplatin) as your main treatment. The study takes place across 25 hospital sites in China, with an enrollment period of approximately 16 months. Your treatment plan would be guided by your cancer's specific genetic profile, and you would have regular visits to monitor how you respond to the medication and manage any side effects.

AI-generated summary from trial data · Jun 18, 2026 · Not medical advice

Trial locations(33 sites)

China

Research Site, Beijing

Research Site, Chengdu